GlassScriptPhysician profile
Jo Ann Tedeschi
NPI 1336230028
$6,553.45
in general payments reported to CMS, 2019-2025
32 companies · $1,659 in 2025
The $1,659 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $762 · 2022: $1,709 · 2023: $1,322 · 2024: $1,102 · 2025: $1,659.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,083.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,082.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $695.81 | 2023-2025 | Gemtesa, Orgovyx |
| Janssen Biotech, INC. | $680.45 | 2021-2025 | Erleada, Akeega, Carvykti |
| Antares Pharma, INC. | $653.46 | 2021-2025 | Xyosted, Tlando, Nocdurna |
| Astellas Pharma US INC | $586.68 | 2021-2025 | Xtandi, Myrbetriq |
| Abbvie INC. | $561.25 | 2021-2025 | |
| Urogen Pharma, INC. | $377.23 | 2022-2025 | Jelmyto |
| Urovant Sciences INC | $309.48 | 2022 | |
| Merck Sharp & Dohme LLC | $297.85 | 2021-2025 | Keytruda, Lynparza, Welireg |
| 180 Medical, INC. | $272.69 | 2021-2025 | Gentlecath Glide, Gentlecath |
| Pfizer INC. | $245.94 | 2021-2025 | |
| Tolmar, INC. | $239.13 | 2023-2025 | Eligard, Jatenzo |
| Ferring Pharmaceuticals INC. | $175.76 | 2024-2025 | Adstiladrin |
| Medtronic, INC. | $150.89 | 2022-2025 | Interstim |
| Axonics, INC. | $147.98 | 2024 | Axonics, Bulkamid |
| Hollister Incorporated | $132.77 | 2021-2023 | Infyna Chic |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $111.05 | 2022-2023 | Xiaflex, Aveed |
| Tolmar Pharmaceuticals, INC. | $106.90 | 2021-2022 | |
| Myovant Sciences INC. | $88.00 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $82.51 | 2025 | Givlaari |
| Halozyme INC | $80.76 | 2023 | |
| Myriad Genetic Laboratories, INC. | $73.22 | 2021-2024 | Prolaris |
| Coloplast Corp | $64.30 | 2021-2023 | Speedicath |
| Allergan, INC. | $59.68 | 2021 | |
| Blue Earth Diagnostics | $56.61 | 2021 | |
| Amgen INC. | $56.46 | 2022 | |
| Novartis Pharmaceuticals Corporation | $55.07 | 2024-2025 | |
| Endo USA, INC. | $52.23 | 2025 | Xiaflex, Aveed |
| Boston Scientific Corporation | $37.67 | 2025 | Spaceoar Vue System - 10ml |
| Dendreon Pharmaceuticals LLC | $34.92 | 2025 | Provenge |
| Tempus Ai, INC | $29.64 | 2025 | Xt Cdx |
| Mission Pharmacal Company | $20.57 | 2022 | |
| Rochester Medical Corporation | $16.49 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jo Ann Tedeschi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.